SCHEMBL4517477

SCHEMBL4517477

[NH]C(=S)Nc1ncccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 6/20 0.40
ALDH1A1 P00352 4/20 0.39
NPC1 O15118 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 3/20 0.36
GAA P10253 2/20 0.36
MAPT P10636 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
TP53 P04637 1/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35
CCR6 P51684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL360111 0.75 MAPT (0.52) LMNAHTTRAB9AALDH1A1NPC1
SCHEMBL3808864 0.75 LMNA (0.52) LMNAHTTRAB9AALDH1A1NPC1
SCHEMBL1467809 0.73 RAB9A (0.61) LMNARAB9AALDH1A1NPC1SMN1; SMN2
SCHEMBL6961244 0.70 LMNA (0.52) LMNAHTTRAB9AALDH1A1NPC1
SCHEMBL2780925 0.70 LMNA (0.42) LMNAHTTALDH1A1KDM4EGAA
SCHEMBL8977716 0.70 CTH (0.44) LMNAHTTRAB9ANPC1SMN1; SMN2
SCHEMBL23566413 0.69 LMNA (0.56) LMNAHTTRAB9AALDH1A1NPC1
SCHEMBL841777 0.67 RAB9A (0.59) LMNAHTTRAB9AALDH1A1NPC1
SCHEMBL4303429 0.67 LMNA (0.54) LMNAHTTRAB9AALDH1A1NPC1
SCHEMBL4512996 0.66 CYP1A2 (0.71) HTTRAB9AALDH1A1NPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233960-A1 Kinase Inhibitors DEVGEN NV (BE) 2009-09-17 US disclosed
EP-1934181-A2 KINASE INHIBITORS Devgen NV (BE) 2008-06-25 EP disclosed
WO-2007042321-A2 KINASE INHIBITORS DEVGEN N.V. (BE) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233960-A1 Kinase Inhibitors ROCK1, MAP3K1, MAP3K11 LMNA 878/4885HTT 1131/4885RAB9A 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.